Astaxanthin induces NADPH oxidase activation and receptor-interacting protein kinase 1-mediated necroptosis in gastric cancer AGS cells

SORI KIM, HANBIT LEE, JOO WEON LIM and HYEYOUNG KIM

Department of Food and Nutrition, Brain Korea 21 FOUR Project, College of Human Ecology, Yonsei University, Seoul 03722, Republic of Korea

Received July 21, 2021; Accepted September 22, 2021

DOI: 10.3892/mmr.2021.12477

Abstract. Astaxanthin (ASX), a red-colored xanthophyll carotenoid, functions as an antioxidant or pro-oxidant. ASX displays anticancer effects by reducing or increasing oxidative stress. Reactive oxygen species (ROS) promote cancer cell death by necroptosis mediated by receptor-interacting protein kinase 1 (RIP1) and RIP3. NADPH oxidase is a major source of ROS that may promote necroptosis in some cancer cells. The present study aimed to investigate whether ASX induces necroptosis by increasing NADPH oxidase activity and ROS levels in gastric cancer AGS cells. AGS cells were treated with ASX with or without ML171 (NADPH oxidase 1 specific inhibitor), N-acetyl cysteine (NAC; antioxidant), z-VAD (pan-caspase inhibitor) or Necrostatin-1 (Nec-1; a specific inhibitor of RIP1). As a result, ASX increased NADPH oxidase activity, ROS levels and cell death, and these effects were suppressed by ML171 and NAC. Furthermore, ASX induced RIP1 and RIP3 activation, ultimately inducing mixed lineage kinase domain-like protein (MLKL) activation, lactate dehydrogenase (LDH) release and cell death. Moreover, the ASX-induced decrease in cell viability was reversed by Nec-1 treatment and RIP1 siRNA transfection, but not by z-VAD. ASX did not increase the ratio of apoptotic Bax/anti-apoptotic Bcl-2, the number of Annexin V-positive cells, or caspase-9 activation, which are apoptosis indices. In conclusion, ASX induced necroptotic cell death by increasing NADPH oxidase activity, ROS levels, LDH release and the number of propidium iodide-positive cells, as well as activating necroptosis-regulating proteins, RIP1/RIP3/MLKL, in gastric cancer AGS cells. The results of this study demonstrated the necroptotic effect of ASX on gastric cancer AGS cells, which required NADPH oxidase activation and RIP1/RIP3/MLKL signaling in vitro.

Introduction

Astaxanthin (ASX) is a naturally occurring red-colored oxygenated carotenoid that is present in microalgae, salmon, trout and shrimp (1). Owing to its structure, which consists of a long backbone and hydroxyl and keto moieties at each polar end, ASX has especially powerful antioxidant capacity compared with other carotenoids (2). ASX has no adverse effects (3), and there is evidence of a reduction in biomarkers of oxidative stress and inflammation with ASX administration (4).

ASX has been shown to inhibit cancer cell proliferation by reducing or increasing oxidative stress (5-10). It has been reported that ASX (100-300 µM) decreases NF-κB and Wnt/β-catenin levels, thereby inhibiting hepatic cancer cell proliferation (5). ASX (50 and 100 µM) has been shown to inhibit the proliferation of Kato-III and SNU cells by suppressing cell cycle progression (6). With respect to antioxidant activity in anticancer mechanisms, ASX (50-150 µM) is known to induce apoptosis by increasing the expression levels of apoptotic Bax and caspase-3, but decreasing anti-apoptotic Bcl-2 levels in colorectal cancer LS-180 cells (7). Kochi et al (8) showed that ASX treatment inhibited azoxymethane-induced neoplastic lesions in the colonic mucosa of mice. ASX administration reduced serum levels of hydroperoxides, an oxidative stress marker, but increased the colonic mucosal levels of antioxidant enzymes (superoxide dismutase, catalase and glutathione peroxidase). These studies suggest that ASX reduces oxidative stress-mediated cancer cell growth.

By contrast, recent studies have reported the pro-oxidant effects of ASX on cancer cells. In one study, ASX (10, 25, 50 and 100 µg ml⁻¹) induced cell death in a dose- and time-dependent manner (24, 48 and 72 h) in human non-small cell lung cancer A549 cells (9). ASX (50 µg ml⁻¹) increased reactive oxygen species (ROS) levels (195% of untreated cells) after 4 h of culture in A549 cells (9). In breast cancer MCF-7 cells, ASX (20, 30, 40 and 50 µM) decreased cell viability in a dose- and time-dependent manner (24, 28 and 72 h culture). Cells
cultured for 48 h with ASX (20 µM) increased ROS levels to 153% of that of the untreated cells (10). Therefore, ASX may exhibit its anticancer effect through the production of ROS and ROS-mediated death signaling pathways.

Necroptosis is programmed necrosis, which is regulated by necroptotic regulators, such as receptor-interacting protein kinase 1 (RIP1), RIP3 and mixed lineage kinase domain-like protein (MLKL) (11,12). Upon stimulation, including the activation of Toll-like receptors (13), T cell receptors (14) and the TNF receptor superfamily (15), the serine/threonine kinase activity of RIP1 and RIP3 increases, and consequent phosphorylation of RIP1 and RIP3 forms a RIP1-RIP3 heterodimeric scaffold complex. However, necrosis represents a form of non-programmed cell death. Therefore, necrosis is not regulated by necroptotic regulators, such as RIP1, RIP3 and MLKL (16).

After formation of the RIP1-RIP3 heterodimeric scaffold complex, free RIP3 is recruited and auto-phosphorylated. This allows the recruitment of MLKL to form the necrosome (17,18). Phosphorylated MLKL translocates to the plasma membrane and oligomerizes into complexes, leading to plasma membrane rupture, thereby acting as an executioner of necroptosis (13). Dysregulation of necroptotic proteins results in cancer development (19). RIP3 is lower in breast and colorectal cancer cells than in healthy cells, and low RIP3 expression levels are associated with poor survival in patients with cancer (12,20). MLKL levels are lower in gastric cancer tissues than in normal tissues (21).

ROS activate RIP1 autophosphorylation and contribute to RIP3 recruitment into the necrosome (22,23). NADPH oxidase produces large amounts of ROS upon exposure to various stimuli (24). Thus, NADPH oxidase activation may mediate necroptosis by activating RIP1-RIP3-MLKL signaling in cancer cells.

The present study aimed to determine whether ASX induces necroptosis by activating necroptotic proteins (RIP1, RIP3 and MLKL) and cell death [by determining lactate dehydrogenase (LDH) release, propidium iodide (PI)-positive cells and cell viability] in gastric cancer AGS cells. In addition, to investigate whether ASX-induced necroptosis is induced by NADPH oxidase activation and increased ROS levels, the cells were treated with the NADPH oxidase inhibitor ML171 or antioxidant N-acetylcysteine (NAC) prior to ASX treatment. Moreover, to assess whether ASX affects the viability of normal gastric epithelial cells, normal RGM-1 cells were treated with ASX, and cell viability and NADPH oxidase activity were measured.

Materials and methods

Materials. ASX (cat. no. SML0982), necrotatin-1 (Nec-1; the stable variant; cat. no. 5042970001), z-VAD-fmk (cat. no. 627610), ML171 (cat. no. 492002) and N-acetylcysteine (NAC; cat. no. A7250) were purchased from Sigma-Aldrich (Merck KGaA). Dichlorofluorescein diacetate (DCF-DA; cat. no. D399) was purchased from Molecular Probes (Thermo Fisher Scientific, Inc.). RPMI-1640 medium (cat. no. 31800022) was purchased from Gibco (Thermo Fisher Scientific, Inc.). MuLV reverse transcriptase (cat. no. M1705) was obtained from Promega Corporation. The protease inhibitor complex (cOmplete™; cat. no. 11697498001) was obtained from Roche Diagnostics GmbH. Antibodies against caspase-9 (cat. no. sc-81663), Bcl-2 (cat. no. sc-492), Bax (cat. no. sc-526) and actin (cat. no. sc-47778) were obtained from Santa Cruz Biotechnology, Inc. Antibodies against phosphorylated (p)-RIP1 (cat. no. 65746) and p-MLKL (cat. no. 91689) were obtained from Cell Signaling Technology, Inc. The antibody against RIP1 (cat. no. 610458) was obtained from BD Pharmingen (BD Biosciences). Antibodies against RIP3 (cat. no. ab56164), p-RIP3 (cat. no. ab209384) and MLKL (cat. no. ab183770) were obtained from Abcam. All other reagents were obtained from Sigma-Aldrich (Merck KGaA). ASX, NEC-1, z-VAD-fmk and ML171 were dissolved in dimethyl sulfoxide (DMSO). Cells incubated with DMSO alone (<0.3%) served as controls (vehicle alone).

Cell line and culture conditions. The human gastric cancer cell line AGS (ATCC CRL-1739; gastric adenocarcinoma) was purchased from the American Type Culture Collection and cultured in RPMI-1640 medium with 10% fetal bovine serum (FBS; Gibco; Thermo Fisher Scientific, Inc.), 2 mM glutamine and antibiotics (100 U/ml penicillin and 100 µg/ml streptomycin). The cells were cultured at 37°C in a humidified atmosphere with 95% air and 5% CO2.

The normal rat gastric epithelial cell line, RGM-1, was obtained from the RIKEN BioResource Center. RGM-1 cells were grown in a 1:1 mixture of Dulbecco's modified Eagle's medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) and Ham's F-12 medium (Gibco; Thermo Fisher Scientific, Inc.) supplemented with 20% newborn calf serum (Gibco; Thermo Fisher Scientific, Inc.), 100 U/ml penicillin and 100 µg/ml streptomycin. The cells were cultured at 37°C in a humidified atmosphere with 95% air and 5% CO2.

Experimental protocol. For all treatments, the cells were cultured at 37°C. For the time-course experiment to determine ROS levels and necroptotic markers, the cells were treated with 20 µM ASX and cultured for 0.5, 1 and 2 h (for ROS levels) or 2, 4 and 6 h (for the mRNA and protein expression levels of RIP1, RIP3, MLKL, and p-RIP1, p-RIP3 and p-MLKL levels).

For the concentration-course experiment to assess ROS levels and cell viability, the cells were treated with ASX (5, 10 or 20 µM) for 2 h (for ROS determination) and 24 h (for analysis of cell viability). For the assessment of ROS levels, NADPH oxidase activity, cell viability, LDH release and Hoechst 33342/propidium oxide (PI) double staining, the cells were pretreated with ML171 (2 µM), NAC (1 mM), Nec-1 (25 µM) or z-VAD-fmk (10 µM) for 1 h and treated with 20 µM ASX for 2 h (to measure levels of ROS and NADPH oxidase activity) or 24 h (for cell viability, LDH release and Hoechst 33342/PI double staining).

To assess the role of RIP1 in ASX-induced cell death, cells were transfected with RIP1 small interfering (si)RNA or negative control (NC) siRNA and treated with ASX (20 µM) for 24 h, and the number of viable cells was counted.

To determine the effect of ASX on caspase-9 activation, the levels of Bax and Bcl-2, and Annexin V-FITC/PI double staining, the cells were treated with 20 µM ASX for 24 h. Western blot analysis was used to determine the levels of pro-caspase-9 and cleaved caspase-9. Fluorescence images
of AGS cells were obtained by Annexin V-FITC/PI double staining.

To determine whether ASX induced cell death and activated NADPH oxidase in normal cells, normal rat gastric epithelial cells (RGM-I) were treated with 20 µM ASX for 2 h (to measure NADPH oxidase activity) or different concentrations (5, 10 or 20 µM) of ASX for 24 h (for cell viability).

**Determination of intracellular ROS levels.** 2'-7'-Dichlorofluorescin diacetate (DCFH-DA) was used to measure intracellular levels of ROS. This method is used to detect hydrogen peroxide and hydroxyl radicals (25). The cells were seeded (6x10^4 cells per well) in 6-well plates and incubated with 10 µM DCF-DA for 30 min. The cells were then washed and scraped into 1 ml PBS. DCF was measured (excitation/emission at 495/535 nm) using a VICTOR5 multilabel counter (PerkinElmer, Inc.). Intracellular ROS levels were expressed in terms of relative increases.

**Cell viability measurement.** The cells were plated in a 24-well plate (1x10^4 cells per well) and cultured for 24 h with or without treatment. Viable cell numbers were determined by direct counting using a hemocytometer based on a trypan blue exclusion test (0.2% trypan blue; Sigma-Aldrich; Merck KGaA). The mean number of viable cells that were not treated with ASX (untreated) was set to 100%.

**Reverse transcription-quantitative PCR (RT-qPCR) analysis.** Total RNA was isolated using the TRIzol® reagent (Invitrogen; Thermo Fisher Scientific, Inc.). RNA was converted to cDNA by reverse transcription using MuLV reverse transcriptase. The reaction conditions were as follows: 23˚C for 10 min, 37˚C for 60 min and 95˚C for 5 min. cDNA was used for qPCR. qPCR was conducted in triplicate using SYBR-Green Real-time PCR Master Mix (Toyobo Life Science). RIP1 primers (forward, 5'-AGAGCTCCAGTGGCCATAAA-3' and reverse, 5'-CTGCTCTTGAGCTGAGACAGG-3') were used to generate a 109-bp PCR product, RIP3 primers (forward, 5'-GACTCCCGCTTCAACTGCATTTTCGTTTG-3') were used to generate a 124-bp PCR product, and MLKL primers (forward, 5'-AGAAGGACT-3' and reverse, 5'-TACGCAGGATGTTGGGAGAT-3') were used to generate a 124-bp PCR product. For β-actin, the forward primer was 5'-ACCAACTGGAACGACATGGAG-3' and the reverse primer was 5'-TGAGGATCTCCATGAGTTAGTC-3', yielding a 349-bp PCR product. cDNA was amplified by 45 cycles of denaturation at 95˚C for 30 sec, annealing at 55˚C for 30 sec and extension at 72˚C for 30 sec. During the first cycle, the 95˚C step was extended to 3 min. Amplification specificity was determined using the 2^ΔΔCt method (26). Levels of the target transcript were normalized to β-actin endogenous control and were constantly expressed in the group.

**Preparation of cell extracts.** Preparation of whole-cell extracts, membrane fractions and cytosolic fractions was performed as previously described (27). Briefly, the cells were harvested by treatment with trypsin/EDTA, washed and centrifuged at 1,000 x g at 21-23˚C for 5 min. The cell pellets were resuspended in lysis buffer containing 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM Tris (pH 7.4) and protease inhibitor complex. The resulting mixture was centrifuged at 10,000 x g at 21-23˚C for 15 min. The supernatants were collected and used as whole-cell extracts. To prepare the cytosolic and membrane fractions, the supernatant was separated by centrifugation at 100,000 x g at 21-23˚C for 1 h. The membrane fraction was obtained by resuspending the pellet in lysis buffer containing 50 mM HEPES (pH 7.4), 150 mM NaCl, 1 mM EDTA and 10% glycerol. The supernatant was used as the cytosolic fraction. The protein concentration was determined using the Bradford assay.

**Western blot analysis.** Whole cell extracts were isolated from cells by using lysis buffer containing 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, 25 mM Tris (pH 7.4) and protease inhibitor complex (Complete; Roche Diagnostics GmbH). The protein concentration was determined using the Bradford assay. Whole cell extracts were loaded onto 8-10% SDS-PAGE gels (40-60 µg protein per lane) and separated by electrophoresis under reducing conditions. Proteins were transferred onto nitrocellulose membranes via electroblotting. The membranes were blocked using 3% non-fat dry milk in Tris-buffered saline and 0.2% Tween-20 (TBST) for 1 h at room temperature. The membrane was incubated with antibodies against caspase-9 (1:1,000), actin (1:4,000), RIP1 (1:1,000), p-RIP1 (1:1,000), RIP3 (1:1,500), p-RIP3 (1:1,000), MLKL (1:1,500) and p-MLKL (1:1,000) in TBST solution containing 3% dry milk overnight at 4˚C. After washing with TBST, the membrane was incubated with horseradish peroxidase-conjugated anti-mouse (1:3,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) or anti-rabbit (1:4,000; cat. no. sc-2005; Santa Cruz Biotechnology, Inc.) secondary antibodies in TBST solution containing 3% dry milk and anti-rabbit) for 2 h at room temperature. The proteins were visualized by exposure to X-ray film by using an enhanced chemiluminescence (ECL) detection system (cat. no. sc-2048; Santa Cruz Biotechnology, Inc.). Actin was used as the loading control. ImageJ software version 1.52a (National Institutes of Health) was used for densitometry analysis of western blots.

**Measurement of NADPH oxidase activity.** A luciferase assay was used to measure NADPH oxidase activity in the membrane and cytosolic fractions (28). The assay was performed in 50 mM Tris-MES buffer (pH 7.0) containing 2 mM KCN, 10 µM lucigenin and 100 µM NADPH. The reaction was initiated by the addition of 10 µg membrane-extract protein. Photon emission was measured using a microplate reader (Molecular Devices, LLC). For negative control experiments, cytosolic fraction protein was used instead of the membrane-fraction protein.

**PI and Hoechst 33342 double staining.** PI is permeable to necrotic cells and is visible as red fluorescence in nuclear DNA (29). Hoechst staining is a cell-permeable nuclear counterstain that emits blue fluorescence when combined with double-stranded DNA (29). Hoechst dyes are very sensitive to DNA conformation and chromatin status in cells and...
are, therefore, used to detect nuclear damage, such as distin-
guishing condensed pyknotic nuclei in apoptotic cells. PI and
Hoechst 33342 double staining was used to determine necrosis
or apoptosis.

The cells were seeded (6.0x10^4 cells per well in a 6-well
plate) and cultured overnight. PI and Hoechst 33342 were
prepared in PBS to serve as the staining solutions (0.5 mg/ml^1). The
cells were treated with 20 µl staining solution in the
dark and then incubated for 10 min at 37°C. The cells were
removed from the medium and fixed for 10 min with 2 ml cold
methanol at 20-22°C. After the removal of methanol, the cells
were washed with PBS (1 ml) for 5 min, examined under a
laser scanning confocal microscope (Zeiss LSM 880; Carl
Zeiss AG), and photographed. The optical filters for excitation
were 490-630 nm for PI and 350-460 nm for Hoechst. The ratio
of red and blue fluorescence density was quantified by ZEN 2.3
(blue edition) software (Carl Zeiss Microscopy GmbH) and
expressed as the percentage of PI-positive cells.

Annexin V/PI double staining. Annexin V and PI double
staining is used to discriminate between apoptosis and
necrosis; PI-positive staining reflects necrosis and
Annexin V-positive/PI-negative staining reflects apop-
tosis (30). The cells were plated (6.0x10^4 cells per well) in
a 6-well culture plate and then cultured overnight. The cells
were then treated with 20 µM ASX for 24 h. The treated
cells were then washed with ice-cold PBS and incubated
with Annexin V-FITC and PI (FITC Annexin V Apop-
tosis Detection Kit; BD Pharmingen; BD Biosciences) in the dark
according to the manufacturer’s recommendations. The cells
were fixed in 2% paraformaldehyde for 10 min at 20-22°C,
washed three times with 1 ml PBS for 5 min, and then
examined under a laser scanning confocal microscope (Zeiss
LSM 880; Carl Zeiss AG) and photographed.

Transfection of RIP1 siRNA. siGenome SMART pool siRNA for
human RIP1 (5'-CCACUAUGUCUGACGGAAUA-3', 5'-UGA
AUGACGUCACGCAA-3', 5'-GCACAAUAUGACACCU
CAA-3' and 5'-GAUGGAAUCAGGACUCU-3') and the NC
siRNA (siGenome None-Targeting siRNA Pool #1; 5'-UGA
CGACUAACACACUA, 5'-UAAGGCUAUGAGGAGA
UAC-3', 5'-UGAUUGGCGUAGUAUAG-3' and 5'-UGAGA
CGUGGAUUGCUA-3') were obtained from GE Healthcare
Dharmacon, Inc. Cells were transfected with 50 nmol RIP1 or
NC siRNAs by using 1,2-dioleoyl-3-trimethylammonium-
propene (DOTAP), following the manufacturer's instructions
(Invitrogen; Thermo Fisher Scientific, Inc.), and then cultured
for 24 h. Then, 24 h after transfection of RIP1 or NC siRNAs, the
cells were treated with 20 µM ASX.

Measurement of LDH release. LDH release represents the
permeabilization of the plasma membrane, a necrosis
marker (31). LDH release was measured using an LDH assay
kit (cat. no. ab102526; Abcam). Cell lysates were prepared
using lysis buffer containing 0.1 M Tris (pH 7.4) and 10%
Triton X-100. Cell lysates were centrifuged at 10,000 x g for
15 min at 4°C. LDH activity in the culture medium and the
cells was measured, as previously described (32). LDH release
was quantified as a percentage of the total LDH content (LDH
in the supernatant + LDH inside the cells).

Statistical analysis. All data are expressed as the mean ± stan-
dard error of the mean. All experiments were repeated three
times. Number of each group was ten (n=10). The statistical
differences among groups were evaluated by one-way
analysis of variance (ANOVA) followed by Tukey’s test.
Statistical analysis was performed using SPSS 22.0 software
(IBM Corp.). P<0.05 was considered to indicate a statistically
significant difference.

Results

ASX increases ROS levels and decreases cell viability in AGS
cells. To assess the appropriate culture time and concentration
of ASX for ROS production in AGS cells, ROS levels were
determined using different culture times and various concen-
trations of ASX. The cells were treated with ASX (20 µM) and
cultured for 2 h. As shown in Fig. 1A, 20 µM ASX increased
ROS levels in a time-dependent manner. Furthermore, ROS
levels were highest at 2 h of culture. When the cells were
treated with various concentrations (5, 10 and 20 µM) of ASX
and cultured for 2 h, the highest level of ROS in AGS cells was
obtained with 20 µM ASX (Fig. 1B). Thus, for further studies
on ROS levels, cells were treated with 20 µM ASX for 2 h.

To determine whether ASX induces cell death and activates
NADPH oxidase in normal cells, normal rat gastric epithelial
RGM-1 cells were treated with 20 µM ASX for 2 h (for determi-
nation of NADPH oxidase activity) or different concentrations
(5, 10 or 20 µM) of ASX for 24 h (for cell viability). ASX
had no effect on cell viability or NADPH oxidase in RGM-1
cells (Fig. 1C and D). The results showed that ASX did not
induce death of normal gastric epithelial cells.

ASX increases NADPH oxidase activity, which leads to cell
death in AGS cells. To determine whether ASX-induced ROS
production was linked to NADPH oxidase activation in AGS
cells, the cells were pretreated with ML171, a specific inhibitor
of NADPH oxidase 1, or an antioxidant, NAC, for 1 h, and then
treated with ASX (20 µM) for 2 h. The ASX-induced increase
in ROS levels was decreased by treatment with ML171 and
NAC (Fig. 1E). As shown in Fig. 1F, ASX increased NADPH
oxidase activity, which was reduced by ML171 in AGS cells.
These results indicated that ASX induced NADPH oxidase
activation, leading to increased ROS levels in AGS cells.

To examine whether ASX induces cell death, cell viability
was assessed after 24 h of culture with various concentra-
tions of ASX. ASX reduced cell viability in a dose-dependent
manner (Fig. 2A).

Further, to determine whether NADPH oxidase and ROS
induced ASX- associated cell death, the cells were treated
with ML171 or NAC for 1 h followed by treatment with ASX
for 24 h. As presented in Fig. 2B, both ML171 and NAC inhib-
ited the ASX-induced decrease in cell viability.

To determine whether ML171 or NAC inhibited
ASX-induced necrosis in AGS cells, PI and Hoechst 33342
double staining was performed (Fig. 2C). The density ratio
of the red and blue fluorescence was quantified and expressed
as PI-positive cells (%) (Fig. 2D). The number of necrotic
AGS cells increased after ASX treatment, as indicated by the
increase in the ratio of PI-positive cells. Both ML171 and NAC
reduced the number of PI-positive cells, indicating that NAC
and ML171 blocked ASX-induced necrotic cell death. These results suggested that ASX induced necrosis, which may be mediated by NADPH oxidase and increased ROS levels.

**ASX activates necroptotic proteins in AGS cells.** During necroptosis, the mRNA and protein levels of necroptotic proteins, including RIP1, RIP3 and MLKL, are upregulated (33,34). In the present study, ASX significantly increased the mRNA expression of RIP1 and RIP3 at 4 h compared with the untreated group. However, there were no significant changes in mRNA expression of MLKL by ASX treatment (Fig. 3A).

Total and phospho-specific forms of RIP1, RIP3 and MLKL were confirmed via western blotting to determine whether the effect of ASX on cell death involves necroptosis (Fig. 3B). It was found that ASX increased the protein expression of RIP1, RIP3 and MLKL. Moreover, ASX augmented the activation of RIP1, RIP3 and MLKL, as indicated by the increased levels of the phosphorylated forms of RIP1 and RIP3. These
results suggested the involvement of RIP1/RIP3/MLKL in ASX-induced necroptosis in AGS cells.

To further investigate the role of RIP1 in ASX-induced cell death, a gene silencing approach was used to specifically knock down RIP1. To confirm the inhibitory effect of RIP1 siRNA, the protein expression of RIP1 in AGS cells was measured after transfection with RIP1 or NC siRNA. The protein levels of RIP1 were notably suppressed in cells transfected with RIP1 siRNA compared with those transfected with the NC siRNA (Fig. 3C). ASX did not induce cell death in cells transfected with RIP1 siRNA, whereas ASX reduced the viability of cells transfected with the NC siRNA (Fig. 3C). These results indicated that ASX-induced cell death may occur through RIP1-mediated necroptosis.

ASX-induced cell death is suppressed by Nec-1, but not by z-VAD, in AGS cells. To determine whether ASX-induced cell death was necroptotic, the cells were treated with Nec-1 or z-VAD for 1 h prior to treatment with ASX for 24 h. Nec-1 is known to be a selective inhibitor of RIP1 (35). As shown in Fig. 4A and B, ASX-induced cell death and LDH release were inhibited by the necroptosis inhibitor Nec-1. A pan-caspase inhibitor, z-VAD, as an inhibitor of apoptosis, did not affect the ASX-induced increase in LDH release and cell death. These results suggested that ASX may induce necroptosis, but not apoptosis.

To determine whether ASX triggered necrotic cell death in AGS cells, PI and Hoechst 33342 double staining was performed (Fig. 4C). Hoechst 33342 is a bis-benzamide derivative that binds to AT-rich sequences in the minor groove of double-stranded DNA. Thus, this fluorescent stain is commonly used to visualize nuclei in microscopic studies (27). The plasma membrane-permeable dye PI can be detected in the necrotic cells. In the present study, Hoechst 33342 stained the nuclei of all cells, including healthy cells, producing blue fluorescence. However, live or apoptotic cells are impermeable...
to PI, which intensely stains necrotic cells red. As presented in Fig. 4C, AGS cells that underwent ASX treatment showed more necrotic cells, as determined by the increased ratio of PI-positive cells (Fig. 4D). Nec-1, a necroptosis inhibitor, decreased the number of PI-positive cells. However, z-VAD did not affect the ASX-induced increase in PI-positive cells, as determined by the ratio of red to blue fluorescence. These results showed that Nec-1 blocked ASX-induced necrotic cell death in AGS cells, suggesting that ASX may induce necroptosis in AGS cells.

**ASX does not induce apoptosis in AGS cells.** Caspase-9 activation amplifies the apoptosis cascade by activation of caspase-3 and other apoptosis mediators (36). Thus, the effect of ASX on caspase-9 activation in cells was determined. ASX did not increase the levels of active caspase-9 (Fig. 4E). As an index of apoptosis, the ratio of Bax/Bcl-2 was determined in cells treated with or without ASX (Fig. 4F). The Bax/Bcl-2 ratio was not affected by ASX. To determine whether ASX triggered apoptotic or necrotic cell death, double staining with Annexin V-FITC and PI was performed (Fig. 4G). Annexin V is a sensitive marker for detecting early apoptosis (30). Apoptotic cells can be distinguished from necrotic cells by double staining with PI. Annexin V-FITC and PI double staining easily distinguished apoptotic cells (shown as green fluorescence) from necrotic cells (shown as red fluorescence). ASX did not cause increased green fluorescence, but resulted in increased red fluorescence, indicating that ASX induced necrosis, but not apoptosis. Taken together, these results indicated that ASX-mediated cell death was related to necrosis/necroptosis.

**Discussion**

ASX shows anticancer effects by increasing or decreasing ROS levels, depending on the cell type, ASX concentration or redox state of the cancer cells. A number of studies have demonstrated that ASX serves as an antioxidant because it scavenges singlet oxygen and free radicals (37-39). However, a recent study showed that high-dose administration (5, 15 and 30 mg/kg body weight) of ASX suppresses the activities of antioxidant enzymes (catalase and glutathione peroxidase) in the muscle tissues of mice (40).
As relatively few studies have determined the pro-oxidative activity of ASX, the mechanisms underlying it are not well defined. Previous research has shown that NADPH oxidase is a major source of ROS (41, 42). The present study found that ASX increased NADPH oxidase, indicating that the source of ROS in ASX-treated cells is NADPH oxidase.

High levels of ROS mediate necroptotic cell death by increasing the phosphorylation of RIP1 and RIP3, which
promotes necrosome formation (43-45). Regarding ROS and activation of RIP1/RIP3, RIP1 targets NADPH oxidase and increases ROS production in the plasma membrane in TNF-α-treated mouse fibroblasts (46). ROS increase the expression of RIP1 and RIP3 and their reciprocal binding (44,47) and stabilize this interaction in glioma cells stressed via photodynamic therapy (48). Therefore, ROS may regulate necroptosis by increasing RIP1 and RIP3 protein levels and their interactions. The current study showed that ASX-induced necroptosis was mediated via NADPH oxidase and ROS, as well as the activation of RIP1-RIP3, as Nec-1 (a specific inhibitor of RIP1), NAC (an antioxidant) and ML171 (an NADPH oxidase inhibitor) significantly suppressed the number of PI-positive AGS cells.

RIP3 binds to the plasma membrane and induces the phosphorylation of MLKL, which induces the oligomerization of p-MLKL to induce plasma membrane rupture and necroptosis (49). In the present study, MLKL was activated during ASX-induced necroptosis in AGS cells. The dead cells resulting from necrosis appeared red due to the PI staining. Hoechst 33342 and PI double staining allowed us to distinguish between the typical features of necrosis. Based on the PI and Hoechst 33342 staining results, ASX increased the number of PI-positive cells, which were inhibited by treatment with NAC, ML171 and Nec-1. However, z-VAD did not affect the ASX-induced increase in PI-positive cells. These results demonstrated that ASX-induced cell death occurred via necroptosis. Moreover, ASX did not induce caspase-9 activation. Moreover, in Annexin V/PI double staining, ASX did not increase the number of Annexin-positive cells, but increased the number of PI-positive cells at 24 h. These findings showed that ASX did not induce apoptosis, but did induce necrotic cell death.

In the present study, it was found that ASX induced an increase in NADPH oxidase activity, ROS production and phosphorylation of RIP1-RIP3/MLKL, leading to cell death in AGS cells. Treatment with the NADPH oxidase 1 inhibitor ML171 suppressed ASX-induced ROS production. High levels of ROS induce mitochondrial dysfunction and increase mitochondrial ROS levels (50,51). Moreover, treatment with ML171, antioxidant NAC and Nec-1, a specific inhibitor of RIP1, and transfection with RIP1 siRNA suppressed ASX-induced necroptosis. Therefore, it was concluded that NADPH oxidase is important in the production of ROS and, consequently, in ROS-mediated activation of RIP1-RIP3-MLK and necroptosis in gastric cancer AGS cells (Fig. 5).
concentrations under high oxygen tension (52,53). Therefore, ASX-induced activation of NADPH oxidase and cell death may be affected by high concentrations of ASX and cellular environmental events in AGS cells.

For bioavailability of ASX in humans, 6-day-consumption of ASX (daily consumption of 250 g salmon; 5 µg ASX per gram of salmon flesh) results in plasma ASX concentrations of 39-52 nM (54). Furthermore, 12-week supplementation of 1 or 3 mg ASX (capsules containing ASX-rich oil) results in plasma concentrations of 18.9 and 62.4 nM, respectively, in Japanese middle-aged and senior subjects (55). Therefore, the concentration of ASX (20 µM) used in the present study is much higher than the concentration that results from dietary intake. These results suggested that a high concentration of ASX should be used to induce gastric cell necroptosis. Further studies should be performed to determine whether high concentrations of ASX induces necroptosis in various cancer cell lines in vitro and in vivo.

In the present study, AGS cells were used to determine the anticancer effects of ASX. The gastric adenocarcinoma AGS cell line is derived from untreated human adenocarcinoma of the stomach. The AGS cell line is a moderately differentiated human gastric adenocarcinoma hyperdiploid cell line. The AGS cell line has been shown to grow in athymic mice (56) and retain the same histochemical and cytological characteristics as the original malignant cells obtained from the patient (57). It is important to characterize human tumor cells in vitro in a detailed manner, as they serve as useful model systems for studies involving heterogeneous responses to anticancer drugs (57). Recently, this cell line has been widely used as a model system for evaluating cancer cell apoptosis (58-60).

AGS cells have more genetic changes and higher growth rates than normal cells (60,61). One example is tripartite motif containing 25 (TRIM25), a member of TRIM proteins that has been implicated in carcinogenesis. AGS cells show high expression of TRIM25, which contributes to higher growth rates compared with normal gastric epithelial cells (61). AGS cells exhibit abnormal expression of microRNA-372 (miR-372) (62). miR-372 maintains oncogene characteristics by targeting tumor necrosis factor-α-induced protein 1-regulated AGS cell growth (63). In a study by Guan et al (64) expression of the oncogene HER-2 in AGS cells was found to be twice that in normal gastric epithelial cells.

In addition, it is known that ROS are produced by several nutrients, such as vitamin C, zeaxanthin and β-carotene, which induce cell death in AGS cells (65-67). Therefore, in the present study, AGS cells were used to determine the anticancer mechanism of ASX.

In a study by Dong et al (68), Nec-1 and NADPH oxidase inhibitor diphenyleneiodonium prevent tumor necrosis factor-α, benzyloxy-carbonyl-Val-Ala-Asp-fluoromethylketone and antimycin A (collectively termed TZA)-induced necroptosis by inhibiting the phosphorylation of RIP3 and MLKL in HK-2 cells. Recent studies have demonstrated that NAC suppresses necroptosis induced by high concentrations of iron or glucose through the inhibition of RIP1 phosphorylation (69,70). These studies suggest that NADPH oxidase-mediated ROS production may induce necroptosis through phosphorylation of RIP1, RIP3 and MLKL (69,70). Further studies are needed to determine whether treatment with ML171, NAC or Nec-1 suppresses ASX-induced expression and activation of RIP1, RIP3 and MLKL in AGS cells.

In conclusion, ASX increased intracellular ROS levels by activating NADPH oxidase, thereby, inducing necroptosis in gastric cancer AGS cells. NADPH oxidase-mediated ROS production may represent an underlying mechanism of ASX-induced necroptosis in gastric cancer AGS cells. Consequently, ASX could be used to treat gastric cancer based on its role in necroptotic signaling.

Acknowledgements
Not applicable.

Funding
This study was financially supported by a grant from the National Research Foundation of Korea, funded by the Korean Government (grant no. NRF-2021R1A2B5B02002353).

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Authors' contributions
HK conceived and designed the experiments. JWL assisted in designing the experiment. SK and HL performed the experiments. SK and JWL analyzed the data. JWL and HK confirm the authenticity of all raw data. SK wrote the paper. HK reviewed and edited the paper. All authors have read and approved the final manuscript.

Ethics approval and consent to participate
Not applicable.

Patient consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

References
1. Yamashita E: Astaxanthin as a medical food. Funct Food Health Dis 3: 254-258, 2013.
2. Kidd P: Astaxanthin, cell membrane nutrient with diverse clinical benefits and anti-aging potential. Altern Med Rev 16: 355-364, 2011.
3. Zhang L and Wang H: Multiple mechanisms of anti-cancer effects exerted by astaxanthin. Mar Drugs 13: 430-4330, 2015.
4. Fassett RG and Coombes JS: Astaxanthin: A potential therapeutic agent in cardiovascular disease. Mar Drugs 9: 447-465, 2011.
5. Li J, Dai W, Xia Y, Chen K, Li S, Liu T, Zhang R, Wang J, Lu W, Zhou Y, et al: Astaxanthin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells via inhibition of NF-κB P65 and Wnt/B-catenin in vitro. Mar Drugs 13: 6064-6081, 2015.
6. Kim JH, Park JJ, Lee BJ, Joo MK, Chun HJ, Lee SW and Bak YT: Astaxanthin inhibits proliferation of human gastric cancer cells by interrupting cell cycle progression. Gut Liver 10: 363‑370, 2016.
7. Hormozi M, Ghoreishi S and Baharvar P: Astaxanthin induces apoptosis and increases activity of antioxidant enzymes in LS‑180 cells. Artif Cells Nanomed Biotechnol 47: 891‑895, 2019.
8. Kochi T, Shimizu M, Sumi T, Kubota M, Shirakami Y, Tanaka T and Moriwaki H: Inhibitory effects of astaxanthin on azoxymethane‑induced polycolonic preneoplastic lesions in C57BL/ KsJ‑db/db mice. BMC Gastroenterol 14: 212, 2014.
9. Tanasawat S, Sukketsiri W, Chonpathomtipkunlert P, Klaypradit W, Sroyyaya M and Hutamekalain P: Apoptotic effect of astaxanthin from white shrimp shells on lung cancer A549 cells. Troy J Pharm Sci 2: 26, 2015.
10. Sowmya PR, Arathi BP, Vijay K, Baskaran V and Lakshminarayana R: Astaxanthin from shrimp efficiently modulates oxidative stress and allied cell death progression in MCF‑7 cells treated synergistically with β‑carotene and lutein from greens. Food Chem Toxicol 106: 58‑59, 2017.
11. Chen D, Yu J and Zhang L: Necroptosis: An alternative cell death program defending against cancer. Biochim Biophys Acta 1865: 228‑236, 2016.
12. Feng X, Song Q, Yu A, Tang H, Peng Z and Wang X: Receptor‑interacting protein kinase 3 is a predictor of survival and plays a tumor‑suppressive role in colorectal cancer. Neoplasma 62: 592‑601, 2015.
13. He S, Liang Y, Shao F and Wang X: Toll‑like receptors activate programmed necrosis in macrophages through a receptor‑interacting kinase‑3‑mediated pathway. Proc Natl Acad Sci USA 108: 20035‑20040, 2011.
14. Chen IL, Tsau JS, Molkentin JD, Komatsu M and Hedrick SM: Mechanisms of necroptosis in T cells. J Exp Med 208: 633‑641, 2011.
15. Lu JV, Chen HC and Walsh CM: Necroptotic signaling in adaptive and innate immunity. Semin Cell Dev Biol 35: 35‑39, 2014.
16. Vanden Berge T, Linkermann A, Jouan‑Lanhoutet S, Walczak H and Vandennabla P: Regulated necrosis: The expanding network of non‑apoptotic cell death pathways. Nat Rev Mol Cell Biol 15: 135‑140, 2014.
17. Mifflin L, Ofengeim D and Yuan J: Receptor‑interacting protein kinase 1 (RIPK1) as a therapeutic target. Nat Rev Drug Discov 19: 553‑571, 2020.
18. Liu Y, Liu T, Lei T, Zhang D, Du S, Girani L, Qi D, Lin C, Tong R and Wang Y: RIP1/RIP3‑regulated necroptosis as a target for multifaceted disease therapy (Review). Int J Mol Med 44: 771‑786, 2019.
19. Lalaoi N and Brumatti G: Relevance of necroptosis in cancer. Immunol Cell Biol 979: 65‑70, 2013.
20. Koo GB, Morgan MJ, Lee DG, Kim WJ, Yoon JH, Koo JS, Lim JW and Kim H: NADPH oxidase: Insights into selected functional and signaling activities. Front Cell Neurosci 10: 332‑336, 2016.
21. Zhou Y, Baker J, Ho K, Kopp S, Koshita Y, Okazaki S, Seidel U, Eggersdorfer M, Rimbach G and Enns S: Necroptotic cell death: Regulation of signal transduction and underlying mechanisms in disease. Front Cell Neurosci 15: 302, 2021.
22. Zhang Y, Su SS, Zhao S, Yang Z, Zhong CQ, Chen X, Cai Q, Yang ZH, Huang D, Wu R, et al: RIP1 autophosphorylation is promoted by mitochondrial ROS and is essential for RIP3 recruitment into necroptosome. Nat Commun 8: 14329, 2017.
23. Moriwaki K and Chan FK: RIP3: A molecular switch for necrosis and inflammation. Genes Dev 27: 1640‑1649, 2013.
24. Skoczylas‑Zezulak K, Toma P, Skoczylas‑Zezulak C, Potel‑Potula A and Buldak RJ: NADPH oxidases: Insights into selected functions and mechanisms of action in cancer and stem cells. Oxid Med Cell Longev 2017: 9420539, 2017.
25. Opara M, Walczak J, Malinska D, van Oppen LM, Szczepanowska J, Koopman WJ and Wieczkowski MR: Quantifying ROS levels using CM‑H2DCFDA and HyPer. Methods 109: 3‑11, 2016.
26. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real‑time quantitative PCR and the 2(‑ΔΔCt) method. Methods 25: 402‑408, 2001.
27. Yang ZH, Huang D, Wu R, et al: Lycopene inhibits oxidative stress‑mediated inflammatory responses in ethanol/palmitoleic acid‑stimulated pancreatic acinar AR42J cells. Int J Mol Sci 22: 2101, 2021.
28. Minkenberg I and Ferber E: Lucigenin‑dependent chemiluminescence as an assay for NAD(P)H‑oxidase activity in particulate fractions of human polymorphonuclear leukocytes. J Immunol Methods 71: 61‑67, 1984.
29. Crowley LC, Marfell BJ, and Waterhouse NJ: Analyzing cell death by nuclear staining with Hoechst 33342. Cold Spring Harb Protoc Sep 1, 2016 (Epub ahead of print). doi: 10.1101/pdb.pro087205.
52. Tapiero H, Townsend DM and Tew KD: The role of carotenoids in the prevention of human pathologies. Biomed Pharmacother 58: 100-110, 2004.

53. Shin J, Song MH, Oh JW, Keum YS and Saini RK: Pro-oxidant actions of carotenoids in triggering apoptosis of cancer cells: A review of emerging evidence. Antioxidants 9: 532, 2020.

54. Rüfer CE, Moeseneder J, Briviba K, Rechtemmer G and Bub A: Bioavailability of astaxanthin stereoisomers from wild (Oncorhynchus spp.) and aquacultured (Salmo salar) salmon in healthy men: A randomised, double-blind study. Br J Nutr 99: 1048-1054, 2008.

55. Miyazawa T, Nakagawa K, Kimura F, Satoh A and Miyazawa T: Plasma carotenoid concentrations before and after supplementation with astaxanthin in middle-aged and senior subjects. Biosci Biotechnol Biochem 75: 1856-1858, 2011.

56. Barati T, Haddadi M, Sadeghi F, Muhammadnejad S, Muhammadnejad A, Heidarian R, Arjomandnejad M and Amanpour S: AGS cell line xenograft tumor as a suitable gastric adenocarcinoma model: Growth kinetic characterization and immunohistochemistry analysis. Iran J Basic Med Sci 21: 678-681, 2018.

57. Barranco SC, Townsend CM Jr, Casartelli C, Macik BG, Burger NL, Boerwinkle WR and Gourley WK: Establishment and characterization of an in vitro model system for human adenocarcinoma of the stomach. Cancer Res 43: 1703-1709, 1983.

58. Park HS, Hong NR, Ahn TS, Kim H, Jung MH and Kim BJ: Apoptosis of AGS human gastric adenocarcinoma cells by melatonin extract of Dictamnus. Pharmacogn Mag 11 (Suppl 2): S529-S536, 2015.

59. Tsai CL, Chiu YM, Ho TY, Hsieh CT, Shieh DC, Lee YJ, Tsay GJ and Wu YY: Gallic Acid induces apoptosis in human gastric adenocarcinoma cells. Anticancer Res 38: 2057-2067, 2018.

60. Ngabire D, Seong YA, Patil MP, Niyonziziye I, Seo YB and Kim GD: Caudatin induces cell apoptosis in gastric cancer cells through modulation of Wnt/β-catenin signaling. Oncol Rep 30: 677-684, 2013.